Diseases, Conditions, Syndromes

Layered controls can significantly curb exposure to COVID-19

As the COVID-19 pandemic unfolded, a team at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory set out to better understand how well face masks, ventilation, and physical distancing can cut down transmission ...

Medications

Subcutaneous mAb may benefit high-risk outpatients with COVID-19

For high-risk outpatients with mild-to-moderate COVID-19, subcutaneously administered monoclonal antibody (mAb) treatment with casirivimab and imdevimab is associated with reduced risk for 28-day hospitalization or death ...

Medical research

Ivermectin does not prevent progression to severe COVID-19

Ivermectin treatment during early illness does not prevent progression to severe disease for high-risk patients with mild-to-moderate COVID-19, according to a study published online Feb. 18 in JAMA Internal Medicine.

page 11 from 40